Camp4 Therapeutics Corp — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Camp4 closed a $50.1M second tranche of private placement (announced September 2025), extending cash runway through end of 2028. The company secured regulatory clearance from Australia's TGA/HREC and Argentina's ANMAT to initiate a Phase 1/2 clinical trial of CMP-002 in SYNGAP-1 patients, with trial launch expected Q4 2026. As of June 30, 2026, cash was $86.4M; including the post-quarter closing, total cash is ~$136.5M—substantially larger than the company's $14.6M market cap.
Why this rating
Financing = 9.3× market cap; extends runway 2.5 years. Regulatory clearance in two jurisdictions + planned Phase 1/2 are material clinical milestones for pre-clinical biotech. Cash sufficiency to 2028 is significant runway extension.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.